Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 8(63), 2019
DOI: 10.1128/aac.00240-19
Links
Tools
First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment
Journal article published in 2019 by
David Tenero,
Geo Derimanov,
Alex Carlton,
John Tonkyn,
Matt Davies,
Simon Cozens,
Stephanie Gresham,
Alison Gaudion,
Adeep Puri,
Morris Muliaditan,
Joaquin Rullas-Trincado,
Alfonso Mendoza-Losana,
Andrew Skingsley,
David Barros-Aguirre 
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Data provided by 
Abstract
This first-time-in-human (FTIH) study evaluated the safety, tolerability, pharmacokinetics, and food effect of single and repeat oral doses of GSK3036656, a leucyl-tRNA synthetase inhibitor. In part A, GSK3036656 single doses of 5 mg (fed and fasted), 15 mg, and 25 mg and placebo were administered. In part B, repeat doses of 5 and 15 mg and placebo were administered for 14 days once daily.